$4.91
+0.11
(+2.29%)▲
2.26%
Downside
Day's Volatility :4.21%
Upside
2.0%
72.51%
Downside
52 Weeks Volatility :92.28%
Upside
71.93%
Period | Aptorum Group Ltd | |
---|---|---|
3 Months | 231.01% | |
6 Months | 158.06% | |
1 Year | 69.61% | |
3 Years | -84.21% |
Market Capitalization | 27.2M |
Book Value | $4.8 |
Earnings Per Share (EPS) | -0.62 |
Wall Street Target Price | 80.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2486.04% |
Return On Assets TTM | -32.3% |
Return On Equity TTM | -37.4% |
Revenue TTM | 431.4K |
Revenue Per Share TTM | 0.1 |
Quarterly Revenue Growth YOY | -100.0% |
Gross Profit TTM | 81.9K |
EBITDA | -9.6M |
Diluted Eps TTM | -0.62 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.64 |
EPS Estimate Next Year | -0.84 |
EPS Estimate Current Quarter | -0.27 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 1529.33%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 383.5K | - |
Net Income | -14.8M | ↑ 482.22% |
Net Profit Margin | -3.9K% | - |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 535.2K | ↑ 39.57% |
Net Income | -20.9M | ↑ 40.61% |
Net Profit Margin | -3.9K% | ↓ 28.87% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 911.5K | ↑ 70.32% |
Net Income | 7.1M | ↓ 133.89% |
Net Profit Margin | 775.29% | ↑ 4672.13% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.5M | ↑ 69.15% |
Net Income | -25.3M | ↓ 457.84% |
Net Profit Margin | -1.6K% | ↓ 2415.5% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.3M | ↓ 15.95% |
Net Income | -5.3M | ↓ 78.98% |
Net Profit Margin | -410.1% | ↑ 1230.11% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 431.4K | ↓ 66.71% |
Net Income | -2.8M | ↓ 46.85% |
Net Profit Margin | -654.8% | ↓ 244.7% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | -1.3M | - |
Net Income | -2.2M | - |
Net Profit Margin | 177.14% | - |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 527.5K | ↓ 142.03% |
Net Income | -1.9M | ↓ 15.19% |
Net Profit Margin | -357.42% | ↓ 534.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 768.4K | ↑ 45.68% |
Net Income | -7.9M | ↑ 319.8% |
Net Profit Margin | -1.0K% | ↓ 672.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 431.4K | ↓ 43.86% |
Net Income | -5.5M | ↓ 30.67% |
Net Profit Margin | -1.3K% | ↓ 242.05% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 45.1M | ↑ 42.82% |
Total Liabilities | 12.3M | ↑ 826.46% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 24.0M | ↓ 46.86% |
Total Liabilities | 9.1M | ↓ 26.17% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 44.2M | ↑ 84.65% |
Total Liabilities | 6.1M | ↓ 33.22% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 21.9M | ↓ 50.47% |
Total Liabilities | 4.4M | ↓ 27.6% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 20.9M | ↓ 4.75% |
Total Liabilities | 13.0M | ↑ 196.15% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 20.6M | ↓ 1.09% |
Total Liabilities | 5.3M | ↓ 59.67% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 20.9M | ↓ 13.12% |
Total Liabilities | 13.0M | ↑ 55.73% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 20.9M | ↑ 0.0% |
Total Liabilities | 13.0M | ↑ 0.0% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.4M | ↓ 30.94% |
Total Liabilities | 1.6M | ↓ 87.47% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.4M | ↑ 0.0% |
Total Liabilities | 1.6M | ↑ 0.0% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 20.6M | ↑ 43.21% |
Total Liabilities | 5.3M | ↑ 221.99% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 20.6M | ↑ 0.0% |
Total Liabilities | 5.3M | ↑ 0.0% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -10.0M | ↑ 73.54% |
Investing Cash Flow | -6.1M | ↓ 147.35% |
Financing Cash Flow | 25.5M | ↑ 180.54% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -13.4M | ↑ 33.35% |
Investing Cash Flow | -108.1K | ↓ 98.22% |
Financing Cash Flow | -7.3M | ↓ 128.74% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -15.9M | ↑ 19.05% |
Investing Cash Flow | 1.8M | ↓ 1804.74% |
Financing Cash Flow | 12.4M | ↓ 269.62% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -14.7M | ↓ 8.04% |
Investing Cash Flow | 16.5M | ↑ 796.07% |
Financing Cash Flow | 2.8M | ↓ 77.61% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 3.3B | ↑ 0.0% |
Investing Cash Flow | 1.4M | ↑ 0.0% |
Financing Cash Flow | 32.8B | ↑ 0.0% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -6.8M | ↓ 100.2% |
Investing Cash Flow | 1.4M | ↑ 0.0% |
Financing Cash Flow | 3.0M | ↓ 99.99% |
Sell
Neutral
Buy
Aptorum Group Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Aptorum Group Ltd | -13.04% | 158.06% | 69.61% | -84.21% | -98.51% |
Moderna, Inc. | 21.03% | 85.08% | 14.68% | -28.27% | 659.22% |
Regeneron Pharmaceuticals, Inc. | 3.22% | 20.54% | 31.88% | 92.14% | 229.83% |
Novo Nordisk A/s | 8.85% | 36.12% | 71.83% | 234.04% | 457.53% |
Vertex Pharmaceuticals Incorporated | 16.81% | 32.76% | 40.6% | 124.79% | 171.36% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Aptorum Group Ltd | NA | NA | NA | -0.64 | -0.37 | -0.32 | NA | 4.8 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.14 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 28.89 | 28.89 | 1.46 | 44.13 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 46.97 | 46.97 | 2.36 | 3.5 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 29.59 | 29.59 | 0.53 | 17.08 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Aptorum Group Ltd | Buy | $27.2M | -98.51% | NA | 0.0% |
Moderna, Inc. | Buy | $54.6B | 659.22% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $108.0B | 229.83% | 28.89 | 29.45% |
Novo Nordisk A/s | Buy | $602.6B | 457.53% | 46.97 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 171.36% | 29.59 | 39.46% |
Geode Capital Management, LLC
Morgan Stanley - Brokerage Accounts
aptorum group limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. it also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. aptorum group limited was incorporated in 2010 and is headquartered in london, the united kingdom.
Organization | Aptorum Group Ltd |
Employees | 3 |
CEO | Mr. Chung Yuen Huen |
Industry | Health Technology |
A Spac I Acquisition Corp
$4.91
+2.29%
Keyarch Acquisition Corp
$4.91
+2.29%
Connexa Sports Technologies Inc
$4.91
+2.29%
Us Value Etf
$4.91
+2.29%
First Wave Biopharma Inc
$4.91
+2.29%
Global X Msci Next Emerging
$4.91
+2.29%
Fat Projects Acquisition Corp
$4.91
+2.29%
Goal Acquisitions Corp
$4.91
+2.29%
Capital Link Global Fintech
$4.91
+2.29%